<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837237</url>
  </required_header>
  <id_info>
    <org_study_id>KBP5074-1-003</org_study_id>
    <nct_id>NCT02837237</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease</brief_title>
  <official_title>A Phase 1, Open-Label Study in Hemodialysis and Non-Hemodialysis Patients With Severe Chronic Kidney Disease to Evaluate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KBP Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KBP Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores the use of KBP-5074 in patients with advanced stages of Chronic Kidney&#xD;
      Disease (CKD) (including patients with severe renal impairment and those on hemodialysis&#xD;
      [HD]) and to assess the safety, tolerability, and pharmacokinetics (PK) of single doses of&#xD;
      KBP-5074 in male and female patients with severe CKD (defined as estimated glomerular&#xD;
      filtration rate [eGFR] ≥15 mL/min/1.73 m2 and ≤29 mL/min/1.73 m2, based on the Modification&#xD;
      of Diet in Renal Disease [MDRD] equation) and a subset of patients requiring HD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, multicenter, open-label, 2-part study designed to assess the PK, safety,&#xD;
      and tolerability of KBP-5074 in patients undergoing HD and non-HD patients with severe CKD&#xD;
      (defined using the eGFR ≥15 mL/min/1.73 m2 and ≤29 mL/min/1.73 m2 based on the MDRD&#xD;
      equation). The study will be conducted at up to 4 clinical research units (CRUs) in the US.&#xD;
      Approximately 12 patients will be enrolled in the study (a single cohort of 6 patients in&#xD;
      each of Part 1 and Part 2). Parts 1 and 2 of the study will be conducted in parallel. If Part&#xD;
      1 is completed prior to the completion of Part 2, or vice versa, the PK, safety, and&#xD;
      tolerability analyses for the completed study part may proceed as planned and will not be&#xD;
      delayed based on the timing of the other respective study part.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2016</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">December 20, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-related Adverse Events</measure>
    <time_frame>312 hours</time_frame>
    <description>Physical exam, vital signs, EKG, clinical laboratory tests, adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>KBP-5074</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBP-5074</intervention_name>
    <description>In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.&#xD;
In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session.</description>
    <arm_group_label>KBP-5074</arm_group_label>
    <other_name>KBP-5074 mineralocorticoid receptor antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, between 18 and 75 years of age, inclusive.&#xD;
&#xD;
          2. Body mass index (BMI) between 19 and 42 kg/m2, inclusive.&#xD;
&#xD;
          3. Has severe CKD, defined as eGFR ≥15 mL/min/1.73 m2 and ≤29 mL/min/1.73 m2 based on the&#xD;
             IDMS traceable15 MDRD equation, according to laboratory results at Screening (non-HD&#xD;
             patients only [Part 1]). Patients with a prior history of greater than 2 weeks of&#xD;
             dialysis in the past and who have dialyzed in the 6 months prior to dosing on Day 1&#xD;
             will be excluded. Patients who have had temporary dialysis for acute kidney injury&#xD;
             will be allowed at the discretion of the Investigator.&#xD;
&#xD;
          4. Serum potassium between 3.3 and 4.8 mmol/L, inclusive, at both Screening and Check-in&#xD;
             (Day -1) (non-HD patients only [Part 1]). One repeat test will be allowed to exclude&#xD;
             lab error or hemolyzed samples.&#xD;
&#xD;
          5. Is on a hemodialysis schedule for at least 45 days with KT/V ≥1.2 for end-stage renal&#xD;
             disease (ESRD) regardless of the etiology including diabetes, with an average 3&#xD;
             hemodialysis sessions per week (HD patients only [Part 2]).&#xD;
&#xD;
          6. Is a nonsmoker or light smoker (smokes fewer than 10 cigarettes per day). Alcohol&#xD;
             addressed in exclusion.&#xD;
&#xD;
          7. Female patients cannot be pregnant or lactating/breast-feeding and will either be&#xD;
             postmenopausal (female patients who state they are postmenopausal should have had&#xD;
             cessation of menses for &gt;1 year and have serum follicle stimulating hormone [FSH]&#xD;
             levels &gt;40 mIU/mL and estradiol &lt;20 pg/mL, surgically sterile (including bilateral&#xD;
             tubal ligation, salpingectomy [with or without oophorectomy], surgical hysterectomy,&#xD;
             or bilateral oophorectomy [with or without hysterectomy]) for at least 3 months prior&#xD;
             to Screening, or will agree to use, from the time of Check-in (Day -1) until 90 days&#xD;
             following the last dose of study drug, the following forms of contraception:&#xD;
             double-barrier method, hormonal contraceptives, barrier with spermicide, diaphragm or&#xD;
             cervical cap with spermicide, intrauterine device, oral, implantable, or injectable&#xD;
             contraceptives, or a sterile sexual partner. All female patients will have a negative&#xD;
             urine or serum pregnancy test result prior to enrollment in the study.&#xD;
&#xD;
          8. Male patients will either be surgically sterile or agree to use, from the time of&#xD;
             Check-in (Day -1) until 90 days following the last dose of study drug, the following&#xD;
             forms of contraception: male condom with spermicide and a female partner who is&#xD;
             sterile or agrees to use hormonal contraceptives, female condom with spermicide,&#xD;
             diaphragm or cervical cap with spermicide, intrauterine device, oral, implantable, or&#xD;
             injectable contraceptives. Male patients will refrain from sperm donation from the&#xD;
             time of Check-in (Day -1) until 90 days following the last dose of study drug.&#xD;
&#xD;
          9. Is capable of understanding the written informed consent, provides signed and&#xD;
             witnessed written informed consent, and agrees to comply with protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any prior or concomitant clinical condition or acute and/or unstable&#xD;
             systemic disease compromising patient inclusion, at the discretion of the&#xD;
             Investigator.&#xD;
&#xD;
          2. Has a history or presence of clinically significant (CS) cardiovascular, pulmonary,&#xD;
             hepatic, gallbladder or biliary tract, hematologic, gastrointestinal, endocrine,&#xD;
             immunologic, dermatologic, neurologic, or psychiatric disease, which in the&#xD;
             Investigator's opinion would not be suitable for the study from patient safety&#xD;
             consideration and could interfere the results of the trial.&#xD;
&#xD;
          3. History of CS hypotension during the 6 months prior to the dose of study drug on Day 1&#xD;
             as determined by the Investigator.&#xD;
&#xD;
          4. History of symptomatic intradialytic hypotension as determined by the Investigator&#xD;
             (mild to moderate decrease in blood pressure during dialysis is allowed; HD patients&#xD;
             only [Part 2]).&#xD;
&#xD;
          5. History of CS hyperkalemia while on an angiotensin converting enzyme inhibitor,&#xD;
             angiotensin receptor blocker, direct renin inhibitor, and/or MRA.&#xD;
&#xD;
          6. Hospitalization for hyperkalemia during the last 6 months prior to the dose of study&#xD;
             drug on Day 1 or hyperkalemia &gt;5.5 mmol/L during the 2 weeks prior to the Screening&#xD;
             visit.&#xD;
&#xD;
          7. History of stroke within 3 months prior to the dose of study drug on Day 1.&#xD;
&#xD;
          8. History of cardiac transplant.&#xD;
&#xD;
          9. History of severe uncontrolled arrhythmia, acute myocardial infarction, or acute&#xD;
             coronary syndrome within 3 months prior to the dose of study drug on Day 1.&#xD;
&#xD;
         10. Clinical diagnosis of heart failure and persistent symptoms (New York Heart&#xD;
             Association Class II to IV) at either the Screening visit or at Check-in (Day 1).&#xD;
&#xD;
         11. History of stomach or intestinal surgery (except that cholecystectomy, appendectomy,&#xD;
             and/or hernia repair will be allowed).&#xD;
&#xD;
         12. History of prescription drug abuse, illicit drug use, or alcohol abuse according to&#xD;
             medical history within 6 months prior to the Screening visit or any alcohol use or for&#xD;
             at least 48 hours prior to dosing on Day 1.&#xD;
&#xD;
         13. History of clinically significant acute or chronic hepatitis (including infectious,&#xD;
             metabolic, autoimmune, genetic, ischemic, or other forms), hepatocirrhosis, or hepatic&#xD;
             tumors.&#xD;
&#xD;
         14. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HbsAg), or hepatitis C (HCV) antibody. If a patient with Severe renal&#xD;
             impairment or on HD has positive test results for HCV antibody but liver function&#xD;
             tests are otherwise not CS, the patient may be included at the Investigator's&#xD;
             discretion.&#xD;
&#xD;
         15. Clinically significant abnormal liver function test at screening or Check-in (Day -1),&#xD;
             defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;1.5&#xD;
             times upper limit of normal (ULN) or total bilirubin &gt;ULN.&#xD;
&#xD;
         16. Recent (within 3 month prior to the dose of study drug on Day 1) or planned coronary&#xD;
             revascularization by angioplasty or cardiovascular surgery (excluding HD vascular&#xD;
             access).&#xD;
&#xD;
         17. Kidney transplant scheduled within the year.&#xD;
&#xD;
         18. Systolic blood pressure &lt;90 or &gt;200 mmHg and/or diastolic blood pressure &lt;60 or &gt;110&#xD;
             mmHg during the Screening visit and before the dose of study drug on Day 1; may be&#xD;
             repeated at the discretion of the Investigator.&#xD;
&#xD;
         19. Positive screen for alcohol or drugs of abuse (except for patients with a positive&#xD;
             drug screen test if it is a result of a prescribed medication from their physician) at&#xD;
             Screening and Check-in (Day -1). Hemodialysis patients will be tested with serum drug&#xD;
             screen at Screening and using salivary testing at Check-in (Day -1).&#xD;
&#xD;
         20. Female is pregnant or breastfeeding within 2 years prior to the dose of study drug on&#xD;
             Day 1 or positive pregnancy test (serum/urine) result during the Screening visit and&#xD;
             before the dose of study drug on Day 1. Patients who have a false positive test&#xD;
             attributable to their post-menopausal state or kidney disease, as determined by the&#xD;
             Investigator, will be allowed to participate.&#xD;
&#xD;
         21. Has a known hypersensitivity to KBP-5074, aldosterone antagonists, or related&#xD;
             compounds.&#xD;
&#xD;
         22. Receipt of any other investigational product within 30 days or 5 half-lives (whichever&#xD;
             is longer) prior to the dose of study drug on Day 1.&#xD;
&#xD;
         23. Currently on a MRA (eg, spironolactone, eplerenone) or potassium sparing diuretics&#xD;
             (eg, amiloride, triamterene).&#xD;
&#xD;
         24. Concomitant use of or treatment with any prescription drugs, herbal products,&#xD;
             vitamins, minerals, and over-the-counter medications within 14 days prior to Check in&#xD;
             (Day -1) and during the study. Exceptions may be made on a case by case basis&#xD;
             following discussion and agreement between the Investigator and the Sponsor. Patients&#xD;
             requiring HD (Part 2) may continue to receive routine medications (including vitamins,&#xD;
             antidepressants, antihypertensive, and low dose aspirin) to maintain their stable&#xD;
             medication regimen.&#xD;
&#xD;
         25. Use of any nutrients known to modulate cytochrome P450 (CYP)3A activity (based on the&#xD;
             KBP-5074 metabolic pathway) or any strong or moderate inhibitors or inducers of&#xD;
             CYP3A4, starting from 14 days prior to dose administration on Day 1 until the final&#xD;
             end of study assessments, including but not limited to the following: inhibitors such&#xD;
             as ketoconazole, miconazole, itraconazole, fluconazole, atazanavir, erythromycin,&#xD;
             clarithromycin, ranitidine, cimetidine, verapamil, and diltiazem and inducers such as&#xD;
             rifampicin, rifabutin, glucocorticoids, carbamazepine, phenytoin, phenobarbital, and&#xD;
             St. John's wort.&#xD;
&#xD;
         26. Participated in strenuous exercise from 48 hours prior to Check-in (Day -1) or during&#xD;
             the study through the final end of study assessment.&#xD;
&#xD;
         27. Has donated or lost a significant volume (&gt;500 mL) of blood or plasma within 30 days&#xD;
             prior to Check-in (Day -1).&#xD;
&#xD;
         28. Is an employee or family member of the Investigator or study site personnel.&#xD;
&#xD;
         29. Has problems understanding the protocol requirements, instructions, study related&#xD;
             restrictions, and/or problems understanding the nature, scope, and potential&#xD;
             consequences of participating in this clinical study.&#xD;
&#xD;
         30. Is unlikely to comply with the protocol requirements, instructions, and/or study&#xD;
             related restrictions (eg, uncooperative attitude, unavailable for follow up call,&#xD;
             and/or improbability of completing the clinical study).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Yang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>KBP Biosciences Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KBP Biosciences USA Inc</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <results_first_submitted>August 15, 2019</results_first_submitted>
  <results_first_submitted_qc>September 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 15, 2019</results_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mineralocorticoids</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02837237/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>KBP-5074</title>
          <description>Single oral dose&#xD;
KBP-5074: In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.&#xD;
In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>KBP-5074</title>
          <description>Single oral dose&#xD;
KBP-5074: In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.&#xD;
In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" lower_limit="37" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124.8" spread="14.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-related Adverse Events</title>
        <description>Physical exam, vital signs, EKG, clinical laboratory tests, adverse events</description>
        <time_frame>312 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>KBP-5074</title>
            <description>Single oral dose&#xD;
KBP-5074: In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.&#xD;
In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Adverse Events</title>
          <description>Physical exam, vital signs, EKG, clinical laboratory tests, adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <desc>An overall summary of the number and percentage of subjects in each category were presented, as well as an overall summary of the number of events in each category. The number and percentage of subjects reporting AEs in each category above were summarized by study part and cohort according to the system organ class (SOC) and preferred term (PT) assigned to the event using the Medical Dictionary for Regulatory Activities (MedDRA) version 19.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>KBP-5074</title>
          <description>Single oral dose&#xD;
KBP-5074: In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.&#xD;
In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>procedural hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>increased creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vincent J. Benn</name_or_title>
      <organization>KBP Biosciences Co., Ltd.</organization>
      <phone>2677996545</phone>
      <email>vince.benn@kbpbiosciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

